Differential expression of p73 splice variants and protein in benign and malignant ovarian tumours
Daniel Zwahlen
Department of Clinical Research, University Hospital Inselspital Bern, Bern, Switzerland
Search for more papers by this authorMario P. Tschan
Department of Clinical Research, University Hospital Inselspital Bern, Bern, Switzerland
Search for more papers by this authorTobias J. Grob
Department of Clinical Research, University Hospital Inselspital Bern, Bern, Switzerland
Search for more papers by this authorUwe R. Peters
Department of Haematology/Oncology, Charité/Virchow-Clinic, Berlin, Germany
Search for more papers by this authorDaniel Fink
Department of Gynaecology, University Hospital Zurich, Zurich, Switzerland
Search for more papers by this authorWilly Haenggi
Department of Gynaecology, University Hospital Inselspital Bern, Bern, Switzerland
Search for more papers by this authorJean-François Cajot
Department of Clinical Research, University Hospital Inselspital Bern, Bern, Switzerland
Search for more papers by this authorAndreas Tobler
Department of Medical Oncology/Haematology, University Hospital Inselspital Bern, Bern, Switzerland
Search for more papers by this authorMartin F. Fey
Department of Medical Oncology/Haematology, University Hospital Inselspital Bern, Bern, Switzerland
Search for more papers by this authorCorresponding Author
Stefan Aebi
Department of Medical Oncology/Haematology, University Hospital Inselspital Bern, Bern, Switzerland
Institute of Medical Oncology, University of Bern, Inselspital, 3010 Bern, Switzerland. Fax: +41 31 382 1237Search for more papers by this authorDaniel Zwahlen
Department of Clinical Research, University Hospital Inselspital Bern, Bern, Switzerland
Search for more papers by this authorMario P. Tschan
Department of Clinical Research, University Hospital Inselspital Bern, Bern, Switzerland
Search for more papers by this authorTobias J. Grob
Department of Clinical Research, University Hospital Inselspital Bern, Bern, Switzerland
Search for more papers by this authorUwe R. Peters
Department of Haematology/Oncology, Charité/Virchow-Clinic, Berlin, Germany
Search for more papers by this authorDaniel Fink
Department of Gynaecology, University Hospital Zurich, Zurich, Switzerland
Search for more papers by this authorWilly Haenggi
Department of Gynaecology, University Hospital Inselspital Bern, Bern, Switzerland
Search for more papers by this authorJean-François Cajot
Department of Clinical Research, University Hospital Inselspital Bern, Bern, Switzerland
Search for more papers by this authorAndreas Tobler
Department of Medical Oncology/Haematology, University Hospital Inselspital Bern, Bern, Switzerland
Search for more papers by this authorMartin F. Fey
Department of Medical Oncology/Haematology, University Hospital Inselspital Bern, Bern, Switzerland
Search for more papers by this authorCorresponding Author
Stefan Aebi
Department of Medical Oncology/Haematology, University Hospital Inselspital Bern, Bern, Switzerland
Institute of Medical Oncology, University of Bern, Inselspital, 3010 Bern, Switzerland. Fax: +41 31 382 1237Search for more papers by this authorAbstract
The p73 gene encodes a protein with substantial structural and functional similarities to the tumour-suppressor p53. Alternative splicing of p73 mRNA leads to expression of 6 known RNA species and proteins (α, β, γ, δ, ϵ, ζ). We analysed the expression of these splice variants in ovarian adenocarcinoma by RT-PCR followed by detection of amplicons with the Southern technique and by immunoblot in 32 malignant and benign epithelial ovarian tumour specimens and 3 ovarian adenocarcinoma cell lines (A2780, 2008, OVCAR-3). p73α mRNA was expressed in all 17 ovarian cancer specimens, and 14 of 17 expressed at least 3 splice variants. In contrast, a different expression pattern was present in the ovarian adenomas: p73α was detected in 6 of 12 benign tumours, and only 1 adenoma expressed 3 splice variants. p73 protein was expressed in 9 of 16 ovarian cancer specimens, in all cell lines and in 1 of 3 borderline tumours. In contrast, none of 9 ovarian adenomas expressed detectable amounts of p73 protein. Expression of p73 mRNA and protein was not correlated with FIGO stage and histological grade, but we observed a significant correlation with over-expression of p53 protein. In summary, epithelial ovarian cancers express a more complex p73 isoform pattern and higher levels of p73 mRNA and protein than ovarian adenomas. Int. J. Cancer 88:66–70, 2000. © 2000 Wiley-Liss, Inc.
REFERENCES
- Agami, R., Blandino, G., Oren, M. and Shaul, Y., Interaction of c-Abl and p73alpha and their collaboration to induce apoptosis. Nature (Lond.), 399, 809-813 (1999).
- Balint, E., Bates, S. and Vousden, K.H., Mdm2 binds p73alpha without targeting degradation. Oncogene, 18, 3923-3929 (1999).
- Berchuck, A. and Carney, M., Human ovarian cancer of the surface epithelium. Biochem. Pharmacol., 54, 541-544 (1997).
- Codegoni, A.M., Bertoni, F., Patregnani, C., Marinetti, E., D'Incalci, M. and Broggini, M., Allelic expression of p73 in human ovarian cancers. Ann. Oncol., 10, 949-953 (1999).
- De Laurenzi, V., Raschellà, G., Barcaroli, D., Annicchiarico-Petruzzelli, M., Ranalli, M., Catani, M.V., Tanno, B., Costanzo, A., Levrero, M. and Melino, G., Induction of neuronal differentiation by p73 in a neuroblastoma cell line. J. biol. Chem., 275, 15226-15231 (2000).
- De Laurenzi, V.D., Catani, M.V., Terrinoni, A., Corazzari, M., Melino, G., Costanzo, A., Levrero, M. and Knight, R.A., Additional complexity in p73: induction by mitogens in lymphoid cells and identification of two new splicing variants epsilon and zeta. Cell Death Differentiation, 6, 389-390 (1999).
- Di Como, C.J., Gaiddon, C. and Prives, C., p73 function is inhibited by tumor-derived p53 mutants in mammalian cells. Mol. cell. Biol., 19, 1438-1449 (1999).
- Dobbelstein, M., Wienzek, S., Konig, C. and Roth, J., Inactivation of the p53-homologue p73 by the mdm2-oncoprotein. Oncogene, 18, 2101-2106 (1999).
- Gong, J.G., Costanzo, A., Yang, H.Q., Melino, G., Kaelin, W.G. Jr., Levrero, M. and Wang, J.Y., The tyrosine kinase c-Abl regulates p73 in apoptotic response to cisplatin-induced DNA damage. Nature (Lond.), 399, 806-809 (1999).
- Harris, C.C., Structure and function of the p53 tumor suppressor gene: clues for rational cancer therapeutic strategies. J. nat. Cancer Inst., 88, 1442-1455 (1996).
- Ikawa, S., Nakagawara, A. and Ikawa, Y., p53 family genes: structural comparison, expression and mutation. Cell Death Differentiation, 6, 1154-1161 (1999).
- Imyanitov, E.N., Birrell, G.W., Filippovich, I., Sorokina, N., Arnold, J., Mould, M.A., Wright, K., Walsh, M., Mok, S.C., Lavin, M.F., Chenevix-Trench, G. and Khanna, K.K., Frequent loss of heterozygosity at 1p36 in ovarian adenocarcinomas but the gene encoding p73 is unlikely to be the target. Oncogene, 18, 4640-4642 (1999).
- Jost, C.A., Marin, M.C. and Kaelin, W.G., Jr., p73 is a human p53-related protein that can induce apoptosis. Nature (Lond.), 389, 191-194 (1997).
- Kaghad, M. and 12 others, Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers. Cell, 90, 809-819 (1997).
- Kasprzak, L., Foulkes, W.D. and Shelling, A.N., Fortnightly review: hereditary ovarian carcinoma. Brit. med. J., 318, 786-789 (1999).
- Kawano, S., Miller, C.W., Gombart, A.F., Bartram, C.R., Matsuo, Y., Asou, H., Sakashita, A., Said, J., Tatsumi, E. and Koeffler, H.P., Loss of p73 gene expression in leukemias/lymphomas due to hypermethylation. Blood, 94, 1113-1120 (1999).
- Lee, C.W. and La Thangue, N.B., Promoter specificity and stability control of the p53-related protein p73. Oncogene, 18, 4171-4181 (1999).
- Levrero, M., De Laurenzi, V., Costanzo, A., Gong, J., Wang, J.Y. and Melino, G., The p53/p63/p73 family of transcription factors: overlapping and distinct functions. J. Cell Sci., 113, 1661-1670 (2000).
- Levrero, M., Laurenzi, V.D., Costanzo, A., Gong, J., Melino, G. and Wang, J.Y., Structure, function and regulation of p63 and p73. Cell Death Differentiation, 6, 1146-1153 (1999).
- Maggiolini, M., Donze, O. and Picard, D., A non-radioactive method for inexpensive quantitative RT-PCR. Biol. Chem., 380, 695-697 (1999).
- Mai, M., Yokomizo, A., Qian, C., Yang, P., Tindall, D.J., Smith, D.I. and Liu, W., Activation of p73 silent allele in lung cancer. Cancer Res., 58, 2347-2349 (1998).
- Ng, S.W., Yiu, G.K., Liu, Y., Huang, L.W., Palnati, M., Jun, S.H., Berkowitz, R.S. and Mok, S.C., Analysis of p73 in human borderline and invasive ovarian tumor. Oncogene, 19, 1885-1890 (2000).
- Nomoto, S., Haruki, N., Kondo, M., Konishi, H., Takahashi, T., Takahashi, T. and Takahashi, T., Search for mutations and examination of allelic expression imbalance of the p73 gene at 1p36.33 in human lung cancers. Cancer Res., 58, 1380-1383 (1998).
- Oren, M., Lonely no more: p53 finds its kin in a tumor suppressor haven. Cell, 90, 829-832 (1997).
- Peters, U.R., Tschan, M.P., Kreuzer, K.A., Baskaynak, G., Lass, U., Tobler, A., Fey, M.F. and Schmidt, C.A., Distinct expression patterns of the p53-homologue p73 in malignant and normal hematopoiesis assessed by a novel real-time reverse transcription-polymerase chain reaction assay and protein analysis. Cancer Res., 59, 4233-4236 (1999).
-
Schittek, B.,
Sauer, B. and
Garbe, C.,
Lack of p73 mutations and late occurrence of p73 allelic deletions in melanoma tissues and cell lines.
Int. J. Cancer,
82,
583-586
(1999).
10.1002/(SICI)1097-0215(19990812)82:4<583::AID-IJC18>3.0.CO;2-G CAS PubMed Web of Science® Google Scholar
-
Scully, R.E.,
Histological typing of ovarian tumours,
2nd ed. Springer-Verlag,
Berlin (1999).
10.1007/978-3-642-58564-7 Google Scholar
-
Shishikura, T.,
Ichimiya, S.,
Ozaki, T.,
Nimura, Y.,
Kageyama, H.,
Nakamura, Y.,
Sakiyama, S.,
Miyauchi, M.,
Yamamoto, N.,
Suzuki, M.,
Nakajima, N. and
Nakagawara, A.,
Mutational analysis of the p73 gene in human breast cancers.
Int. J. Cancer,
84,
321-325
(1999).
10.1002/(SICI)1097-0215(19990621)84:3<321::AID-IJC21>3.0.CO;2-S CAS PubMed Web of Science® Google Scholar
- Takahashi, H., Ichimiya, S., Nimura, Y., Watanabe, M., Furusato, M., Wakui, S., Yatani, R., Aizawa, S. and Nakagawara, A., Mutation, allelotyping, and transcription analyses of the p73 gene in prostatic carcinoma. Cancer Res., 58, 2076-2077 (1998).
- Tannapfel, A., Wasner, M., Krause, K., Geissler, F., Katalinic, A., Hauss, J., Mossner, J., Engeland, K. and Wittekind, C., Expression of p73 and its relation to histopathology and prognosis in hepatocellular carcinoma. J. nat. Cancer Inst., 91, 1154-1158 (1999).
- Thompson, F.H., Taetle, R., Trent, J.M., Liu, Y., Massey-Brown, K., Scott, K.M., Weinstein, R.S., Emerson, J.C., Alberts, D.S. and Nelson, M.A., Band 1p36 abnormalities and t(1;17) in ovarian carcinoma. Cancer Genet. Cytogenet., 96, 106-110 (1997).
- Ueda, Y., Hijikata, M., Takagi, S., Chiba, T. and Shimotohno, K., New p73 variants with altered C-terminal structures have varied transcriptional activities. Oncogene, 18, 4993-4998 (1999).
- Vikhanskaya, F., D'Incalci, M. and Broggini, M., p73 competes with p53 and attenuates its response in a human ovarian cancer cell line. Nucl. Acids Res., 28, 513-519 (2000).
- Yang, A., Walker, N., Bronson, R., Kaghad, M., Oosterwegel, M., Bonnin, J., Vagner, C., Bonnet, H., Dikkes, P., Sharpe, A., McKeon, F. and Caput, D., p73-deficient mice have neurological, pheromonal and inflammatory defects but lack spontaneous tumours. Nature (Lond.), 404, 99-103 (2000).
- Yuan, Z.M., Shioya, H., Ishiko, T., Sun, X., Gu, J., Huang, Y.Y., Lu, H., Kharbanda, S., Weichselbaum, R. and Kufe, D., p73 is regulated by tyrosine kinase c-Abl in the apoptotic response to DNA damage. Nature (Lond.), 399, 814-817 (1999).
- Zaika, A.I., Kovalev, S., Marchenko, N.D. and Moll, U.M., Over-expression of the wild type p73 gene in breast cancer tissues and cell lines. Cancer Res., 59, 3257-3263 (1999).
- Zhu, J., Jiang, J., Zhou, W. and Chen, X., The potential tumor suppressor p73 differentially regulates cellular p53 target genes. Cancer Res., 58, 5061-5065 (1998).
Citing Literature
